Trial watch: Chemotherapy with immunogenic cell death inducers.

Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78

Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ (2013) 1.64

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51

Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49

Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41

Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35

Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35

Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31

Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30

Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology (2014) 1.30

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22

Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22

Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology (2013) 1.21

Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17

Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ (2013) 1.13

Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09

Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04

ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology (2013) 1.01

Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Front Immunol (2014) 1.00

Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96

Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96

Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95

Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94

A role for orexin in cytotoxic chemotherapy-induced fatigue. Brain Behav Immun (2013) 0.93

Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines (Basel) (2015) 0.91

Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology (2012) 0.91

Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress. Oncoimmunology (2014) 0.91

Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of Damage-Associated Molecular Patterns (DAMPs) in human HeLa cells. PLoS One (2014) 0.90

Immune effectors required for the therapeutic activity of vorinostat. Oncoimmunology (2013) 0.89

Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology (2014) 0.86

Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells. Cell Stress Chaperones (2013) 0.85

Meta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome. Oncoimmunology (2014) 0.85

Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology (2013) 0.84

Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. AAPS J (2014) 0.82

Endoplasmic reticulum chaperones and oxidoreductases: critical regulators of tumor cell survival and immunorecognition. Front Oncol (2014) 0.80

Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin). Oncotarget (2016) 0.77

Three steps to breaking immune tolerance to lymphoma: a microparticle approach. Cancer Immunol Res (2015) 0.77

The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. Vaccines (Basel) (2016) 0.75

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ (2008) 10.45

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44

Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21

Molecular mechanisms of cisplatin resistance. Oncogene (2011) 5.20

Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 4.98

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48

Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol (2002) 3.55

Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41

The anthracyclines: will we ever find a better doxorubicin? Semin Oncol (1992) 3.28

Cell death modalities: classification and pathophysiological implications. Cell Death Differ (2007) 3.19

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol (2011) 2.97

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet (2010) 2.83

Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med (2010) 2.79

Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol (2009) 2.54

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol (2010) 2.51

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol (2010) 2.36

Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol (2009) 2.33

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol (2011) 2.26

Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med (2000) 2.25

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol (2011) 2.24

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol (2009) 2.23

Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med (1998) 2.12

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol (2011) 2.08

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ (2008) 2.01

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol (2009) 1.99

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91

Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol (2009) 1.88

Chemotherapy induces ATP release from tumor cells. Cell Cycle (2009) 1.83

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood (2010) 1.77

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev (2011) 1.76

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene (2010) 1.75

Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res (2010) 1.74

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol (2010) 1.71

Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res (1976) 1.70

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood (2008) 1.69

Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer (2007) 1.67

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol (2010) 1.64

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol (2011) 1.63

Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res (2011) 1.62

Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene (2008) 1.60

Programmed necrosis from molecules to health and disease. Int Rev Cell Mol Biol (2011) 1.58

A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51

Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol (2011) 1.46

Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother (2010) 1.38

Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. J Clin Oncol (2011) 1.32

Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res (2010) 1.28

Targeting p53 to mitochondria for cancer therapy. Cell Cycle (2008) 1.26

Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther (2006) 1.10

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol (2011) 1.09

Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol (2007) 1.08

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother (2011) 1.06

Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res (2010) 1.03

Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol (2009) 1.02

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler (2002) 1.01

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol (2010) 0.99

Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev (2007) 0.97

Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res (1990) 0.94

The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer Chemother Pharmacol (2010) 0.89

Cardiotoxicity associated with mitoxantrone. Lancet (1984) 0.87

Acute doxorubicin cardiotoxicity. N Engl J Med (2005) 0.87

Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer. Clin Lung Cancer (2010) 0.85

Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene (2004) 0.85

Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions. Cancer Lett (2010) 0.82

Autophagy in the pathogenesis of disease. Cell (2008) 34.68

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47

The hallmarks of aging. Cell (2013) 14.29

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

The pathophysiology of mitochondrial cell death. Science (2004) 13.87

Mitochondrial membrane permeabilization in cell death. Physiol Rev (2007) 12.72

Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27

Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13

Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99

Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97

Autophagy and aging. Cell (2011) 5.96

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23

Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00

Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75

Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60

Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32

Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30

Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07

The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01

The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci (2005) 3.93

Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82

Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science (2011) 3.74

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41

Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41

Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26

Does autophagy contribute to cell death? Autophagy (2005) 3.21

A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21

Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (2006) 3.21

AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19

Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17

BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy (2007) 3.08

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96

Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle (2009) 2.72

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72

Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62

Necroptosis: a specialized pathway of programmed necrosis. Cell (2008) 2.61

Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med (2003) 2.56

Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res (2006) 2.56

Autophagy regulation by p53. Curr Opin Cell Biol (2010) 2.56

Can autophagy promote longevity? Nat Cell Biol (2010) 2.55

Cell death assays for drug discovery. Nat Rev Drug Discov (2011) 2.51

Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol (2002) 2.47

PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43

The IKK complex contributes to the induction of autophagy. EMBO J (2009) 2.41

Fatty acids trigger mitochondrion-dependent necrosis. Cell Cycle (2010) 2.37

Complex inhibitory effects of nitric oxide on autophagy. Mol Cell (2011) 2.36

An AIF orthologue regulates apoptosis in yeast. J Cell Biol (2004) 2.33

Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res (2010) 2.29

Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol (2012) 2.28

miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res (2010) 2.24

Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol (2011) 2.23

Viral control of mitochondrial apoptosis. PLoS Pathog (2008) 2.21

Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell (2007) 2.20

Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16

Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med (2013) 2.15

Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell (2012) 2.14

Alternative cell death mechanisms in development and beyond. Genes Dev (2010) 2.14

Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene (2003) 2.09

Involvement of p38alpha in the mitotic progression of p53(-/-) tetraploid cells. Cell Cycle (2010) 2.08

Decoding cell death signals in liver inflammation. J Hepatol (2013) 2.05